title: Effect of resveratrol on microcirculation disorder and lung injury following severe acute pancreatitis in rats.
abstract: OBJECTIVE
  To investigate the mechanism of resveratrol underlying the microcirculation disorder and lung injury following severe acute pancreatitis (SAP).
  
  
  METHODS
  Twenty-four rats were divided into 3 groups (SAP, sham and resveratrol groups) randomly. SAP model was established by injecting 4% sodium taurocholate 1 mL/kg through puncturing pancreatic ducts. Sham (control) group (8 rats) was established by turning over the duodenum. Resveratrol was given at 0.1 mg/kg b.m. intraperitoneally. Rats were sacrificed 9 h after SAP was induced. Blood samples were obtained for hemorrheological examination. Lung tissues were used for pathological observation, and examination of microvascular permeability, dry/wet ratio and myeloperoxidase (MPO) activity. Gene expression of intercellular adhesion molecule-1 (ICAM-1) was detected by RT-PCR.
  
  
  RESULTS
  Compared with SAP group, resveratrol relieved the edema and infiltration of leukocytes in the lungs. Resveratrol improved markers of hemorrheology: high VTB (5.77+/-1.18 mPas vs 9.49+/-1.34 mPas), low VTB (16.12+/-3.20 mPas vs 30.91+/-7.28 mPas), PV (4.69+/-1.68 mPas vs 8.00+/-1.34 mPas), BSR (1.25+/-0.42 mm/h vs 0.03+/-0.03 mm/h), VPC (54.67+/-3.08% vs 62.17+/-3.39%), fibrinogen (203.2+/-87.8 g/ L vs 51.3+/-19.1 g/L), original hemolysis (0.45+/-0.02 vs 0.49+/-0.02), and complete hemolysis (0.41+/-0.02 vs 0.43+/-0.02) (P<0.05). Resveratrol decreased the OD ratio of ICAM-1 gene (0.800+/-0.03 vs 1.188+/-0.10), dry/wet ratio (0.74+/-0.02 vs 0.77+/-0.03), microvascular permeability (0.079+/-0.006 vs 0.112+/-0.004) and MPO activity (4.42+/-0.32 vs 5.03+/-0.51) significantly (P<0.05).
  
  
  CONCLUSIONS
  Resveratrol can improve the microcirculation disorder of the lung by decreasing leukocyte-endothelial interaction, reducing blood viscosity, improving the decrease of blood flow, and stabilizing erythrocytes in SAP rats. It may be a potential candidate to treat SAP and its severe complications (ALI).
authors.affiliation: Department of Hepatobiliary Surgery, First Hospital, Xi'an Jiaotong University, Xi'an 710061, Shaanxi Province, China. my176@sohu.com
authors.forename: Yong
authors.initials: Y
authors.lastname: Meng
authors.forename: Mei
authors.initials: M
authors.lastname: Zhang
authors.forename: Jun
authors.initials: J
authors.lastname: Xu
authors.forename: Xue-Min
authors.initials: XM
authors.lastname: Liu
authors.forename: Qing-Yong
authors.initials: QY
authors.lastname: Ma
mesh_terms: D000208:Acute Disease; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D008168:Lung / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D008297:Male; D008833:Microcirculation / Q000187:drug effects; D010195:Pancreatitis / Q000378:metabolism / Q000473:pathology* / Q000503:physiopathology*; D011652:Pulmonary Circulation / Q000187:drug effects*; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D013267:Stilbenes; D000077185:Resveratrol